TRICYCLIC COMPOUNDS AS EGFR INHIBITORS Russian patent published in 2024 - IPC C07D403/12 C07D403/14 C07D471/14 C07D487/04 C07D491/44 C07D513/04 C07D519/00 A61K31/506 A61K31/55 A61K31/675 A61P35/00 

FIELD: chemistry.

SUBSTANCE: group of inventions relates to organic chemistry and includes a compound of formula (I'''), its stereoisomer, pharmaceutically acceptable salt, hydrate, solvate, pharmaceutical composition containing same, method of treating cancer mediated by EGFR, and intermediate compounds of formulas (Va) and (Va'). In formula (I''') R₁ is C_1-6 alkoxy; M is selected from N and CR_a; Z is selected from N and CR₆; Z₁ is selected from N and CR₇; R_a is H; ring A is selected from 7-member heterocyclyl containing 1–2 heteroatoms selected from N and O, or 7-member carbocyclyl, in which 1 or 2 ring atoms can be optionally replaced with -C(=O) and which can also optionally contain as substitute 1–2 groups R_x; ring B is 5–6 membered heteroaryl containing 1–3 heteroatoms selected from N and S, which optionally contains R₂ as a substitute; other substitutes are as defined in the patent claim.

EFFECT: tricyclic compounds of formula (I''') as selective EGFR inhibitors.

13 cl, 2 dwg, 3 tbl, 139 ex